Arthroscopic Versus Open Tennis Elbow Release: 3- to 6-Year Results of a Case-Control Series of 305 Elbows

2013 ◽  
Vol 29 (5) ◽  
pp. 854-859 ◽  
Author(s):  
Eirik Solheim ◽  
Janne Hegna ◽  
Jannike Øyen
Keyword(s):  
Tennis Elbow ◽  
Case Control ◽  
Control Series

Risk factors in lateral epicondylitis (tennis elbow): a case-control study

2012 ◽  
Vol 38 (2) ◽  
pp. 159-164 ◽  
Author(s):  
A. G. Titchener ◽  
A. Fakis ◽  
A. A. Tambe ◽  
C. Smith ◽  
R. B. Hubbard ◽  
...  
Keyword(s):  
Risk Factors ◽  
Case Control Study ◽  
Tennis Elbow ◽  
Lateral Epicondylitis ◽  
Case Control ◽  
Smoking History ◽  
Health Improvement ◽  
Tunnel Syndrome ◽  
Associated Risk Factors ◽  
Control Study

Lateral epicondylitis is a common condition, but relatively little is known about its aetiology and associated risk factors. We have undertaken a large case-control study using The Health Improvement Network database to assess and quantify the relative contributions of some constitutional and environmental risk factors for lateral epicondylitis in the community. Our dataset included 4998 patients with lateral epicondylitis who were individually matched with a single control by age, sex, and general practice. The median age at diagnosis was 49 (interquartile range 42–56) years . Multivariate analysis showed that the risk factors associated with lateral epicondylitis were rotator cuff pathology (OR 4.95), De Quervain’s disease (OR 2.48), carpal tunnel syndrome (OR 1.50), oral corticosteroid therapy (OR 1.68), and previous smoking history (OR 1.20). Diabetes mellitus, current smoking, trigger finger, rheumatoid arthritis, alcohol intake, and obesity were not found to be associated with lateral epicondylitis.

Case Control Series of Intrathecal Autologous Bone Marrow Mesenchymal Stem Cell Therapy for Chronic Spinal Cord Injury

2010 ◽  
Vol 24 (8) ◽  
pp. 702-708 ◽  
Author(s):  
Nirmeen A. Kishk ◽  
Hala Gabr ◽  
Sherif Hamdy ◽  
Lamia Afifi ◽  
Noha Abokresha ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Autologous Bone Marrow ◽  
Case Control ◽  
Convenience Sample ◽  
Control Series ◽  
Cord Injury ◽  
History Of ◽  
Autologous Bone

Background: Autologous bone marrow mesenchymal cells that include stem cells (MSCs) are a clinically attractive cellular therapy option to try to treat severe spinal cord injury (SCI). Objective: To study the possible value of MSCs injected intrathecally to enhance rehabilitation. Methods: This case control, convenience sample included 64 patients, at a mean of 3.6 years after SCI. Forty-four subjects received monthly intrathecal autologous MSCs for 6 months and 20 subjects, who would not agree to the procedures, served as controls. All subjects received rehabilitation therapies 3 times weekly. Subjects were evaluated at entry and at 12 months after completing the 6-months intervention. By the ASIA Impairment Scale, ASIA grading of completeness of injury, Ashworth Spasticity Scale, Functional Ambulation Classification, and bladder and bowel control questionnaire. Results: No differences were found in baseline measures and descriptors between the MSC group and control group. Although a higher percentage of the MSC group increased motor scores by 1-2 points and changed from ASIA A to B, no significant between-group improvements were found in clinical measures. Adverse effects of cells included spasticity and, in 24 out of the 43 patients developed neuropathic pain. One subject with a history of post-infectious myelitis developed encephalomyelitis after her third injection. Conclusion: Autologus MSCs may have side effects and may be contraindicated in patients with a history of myelitis. Their utility in treating chronic traumatic SCI needs further study in pre-clinical models and in randomized controlled trials before they should be offered to patients.

scholarly journals Association ofOPRD1polymorphisms with heroin dependence in a large case-control series

2012 ◽  
Vol 19 (1) ◽  
pp. 111-121 ◽  
Author(s):  
Elliot C. Nelson ◽  
Michael T. Lynskey ◽  
Andrew C. Heath ◽  
Naomi Wray ◽  
Arpana Agrawal ◽  
...  
Keyword(s):  
Case Control ◽  
Heroin Dependence ◽  
Control Series ◽  
Large Case

scholarly journals Association of common missense changes in ELAC2 (HPC2) with prostate cancer in a Japanese case–control series

2002 ◽  
Vol 47 (12) ◽  
pp. 0641-0648 ◽  
Author(s):  
H. Fujiwara ◽  
M. Emi ◽  
H. Nagai ◽  
T. Nishimura ◽  
N. Konishi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Case Control ◽  
Control Series ◽  
Japanese Case

scholarly journals Drainless Parotidectomy Using Tissue Fibrin Sealant -- A Case-Control Study

2021 ◽  
Author(s):  
Oded Cohen ◽  
Hen Chaushu ◽  
Keren Hod ◽  
Tzur Kirshenbaum ◽  
Avi Khafif
Keyword(s):  
Fibrin Sealant ◽  
Statistical Significance ◽  
Length Of Hospital Stay ◽  
Case Control ◽  
Control Group ◽  
Control Series ◽  
Parotid Tumors ◽  
Suction Drain ◽  
Academic Center ◽  
The Impact

Objectives: Drainless parotidectomy has been reported infrequently, mostly in patients undergoing limited partial parotidectomies. Evicel is a fibrin sealant (FS) glue whose use has not been reported in head and neck surgeries so far. The aim of the study was to investigate the impact of drainless parotidectomy using FS on the surgical outcome. Design: A retrospective matched case-control series. Settings: A single academic center, Participants: All cases of patients who underwent drainless parotidectomies, including deep lobe tumors and revision surgeries, were compared to age, sex, body mass index and tumor-matched controls in which a suction drain was inserted. Main outcome measures: length of hospital stay (LOS). Secondary outcomes included post-operative seroma and related complications. Results: A total of 123 patients (41 cases and 82 controls) were included in the study. Pre-operative and intra-operative characteristic did not differ significantly between the FS group and controls. A borderline significance was found for surgery type as the FS group had higher rates of total parotidectomy compared with the control group (25.0% vs. 10.5%, p=0.054). LOS was significantly shorter in the FS group (1.0±0.3 vs. 1.5±0.6 days, p<0.001). The rates of post-operative seroma, aspirations, local infection and post-operative antibiotic treatment were all lower in the FS group compared with the control group, but did not reach statistical significance. Conclusion: A drainless parotidectomy using the EVICEL FS is safe, reduces LOS, and may reduce post-operative seroma and its associated complications. This procedure may be applied to deep parotid tumors, parapharyngeal involvement and revision surgery.

Sign in / Sign up

Export Citation Format

Share Document